Epidermal growth factor receptor (EGFR) expression in cutaneous melanoma: A possible role as prognostic marker

Staibano, S.; Pepe, Stefano; Soyer, Peter; Argenziano, Giuseppe; Somma, Pasquale; Mansueto, Giovanni; Mascolo, Massimo; Bianco, Antonio; Laus, G.; Rosa, Gennaro De

doi:10.1097/00008390-200404000-00030

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The respective percentages for cell viability for A375-P and A375-MA1 were 54 ± 8 and 55 ± 3% at 24 h, 60 ± 6 and 58 ± 9% at 48 h, and 72 ± 4 and 74 ± 6% at 72 h, respectively. These data reveal similar therapeutic activities of EGFR-targeted nanoceria in both of the 2D models, despite the expected increased levels of EGFR expression in more metastatic melanoma. , The reason for this observation, which is the limitations of the 2D models, is discussed subsequently in Section .…”

Section: Resultsmentioning

confidence: 71%

See 1 more Smart Citation

Theranostic Activity of Ceria-Based Nanoparticles toward Parental and Metastatic Melanoma: 2D vs 3D Models

Johnson

Kopecky

Koshy

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

The time interval between the diagnosis of tumor in a patient and the initiation of treatment plays a key role in determining the survival rates. Consequently, theranostics, which is a combination of diagnosis and treatment, can be expected to improve survival rates. Early detection and immediate treatment initiation are particularly important in the management of melanoma, where survival rates decrease considerably after metastasis. The present work reports for the first time the application of fluorescein isothiocyanate (FITC)tagged epidermal growth factor receptor (EGFR)-functionalized ceria nanoparticles, which exhibit intrinsic reactive oxygen species (ROS)mediated anticancer effects, for the EGFR-targeted diagnosis and treatment of melanoma. The theranostic activity was demonstrated using two-dimensional (2D) and three-dimensional (3D) models of parental and metastatic melanoma. Confocal imaging studies confirm the diagnostic activity of the system. The therapeutic efficiency was evaluated using cell viability studies and ROS measurements. The ROS elevation levels are compared across the 2D and 3D models. Significant enhancement in the generation of cellular ROS and absence in mitochondrial ROS are observed in the 2D models. In contrast, significant elevations in both ROS types are observed for the 3D models, which are significantly higher for the metastatic spheroids than the parental spheroids, thus indicating the suitability of this nanoformulation for the treatment of metastatic melanoma.

show abstract

Section: Resultsmentioning

confidence: 71%

“…These data reveal similar therapeutic activities of EGFR-targeted nanoceria in both of the 2D models, despite the expected increased levels of EGFR expression in more metastatic melanoma. 48,62 The reason for this observation, which is the limitations of the 2D models, is discussed subsequently in Section 3.8.…”

Section: Resultsmentioning

confidence: 99%

Theranostic Activity of Ceria-Based Nanoparticles toward Parental and Metastatic Melanoma: 2D vs 3D Models

Johnson

Kopecky

Koshy

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

show abstract

“…And as well as RTKs alteration, overexpression of platelet derived growth factor receptor (PDGFR)-β or siRNA knockdown of PDGFRβ demonstrates the potential role of PDGFRβ signaling in drug resistance, and the introduction of PDGFRβ into untreated cells reduces sensitivity to vemurafenib ( 89 ). In addition, up-regulation of EGFR expression was found in BRAF inhibitor resistant cell lines and resistant tumor biopsies ( 95 ). EGFR activation binds to specific tyrosine residues on the receptor and results in a conformation change of Sos protein, thereby recruiting and activating RAS-GDP, and finally ERK activation induces cell proliferation ( 96 ).…”

Section: The Evolution Of Braf Activationmentioning

confidence: 99%

The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer

et al. 2022

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) is the most common subtype of lung cancer, of which approximate 4% had BRAF activation, with an option for targeted therapy. BRAF activation comprises of V600 and non-V600 mutations, fusion, rearrangement, in-frame deletions, insertions, and co-mutations. In addition, BRAF primary activation and secondary activation presents with different biological phenotypes, medical senses and subsequent treatments. BRAF primary activation plays a critical role in proliferation and metastasis as a driver gene of NSCLC, while secondary activation mediates acquired resistance to other targeted therapy, especially for epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI). Treatment options for different activation of BRAF are diverse. Targeted therapy, especially two-drug combination therapy, is an important option. Besides, immune checkpoint inhibitors (ICIs) would be another option since BRAF activation would be a positive biomarker of tumor response of ICIs therapy. To date, no high level evidences support targeted therapy or immunotherapy as prioritized recommendation. After targeted therapy, the evolution of BRAF includes the activation of the upstream, downstream and bypass pathways of BRAF. In this review, therapeutic modalities and post-therapeutic evolutionary pathways of BRAF are discussed, and future research directions are also provided.

show abstract

“…Epidermal growth factor receptor (EGFRErbB-1; HER1), a transmembrane protein that is a receptor tyrosine kinase for members of the epidermal growth factor family (EGF family) ligands, is reportedly involved in the autocrine growth of melanoma cells [ 69 ]. In BRAFi-resistant cell lines and in resistant tumor biopsies, the upregulation of EGFR expression was reported.…”

Section: The Egfr Signal Transduction Pathwaymentioning

confidence: 99%

“…Therefore, basal EGFR expression may not be used as a predictive biomarker for BRAFi/MEKi treatment [ 74 ]. At the same time, EGFR expression was significantly correlated with metastatic disease status and therefore suggested as prognostic factor in melanoma [ 69 ].…”

Section: The Egfr Signal Transduction Pathwaymentioning

confidence: 99%

Targeted Therapy in Melanoma and Mechanisms of Resistance

Czarnecka

Bartnik

Fiedorowicz

et al. 2020

IJMS

131

101

View full text Add to dashboard Cite

The common mutation BRAFV600 in primary melanomas activates the mitogen-activated protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway and the introduction of proto-oncogene B-Raf (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitors (BRAFi and MEKi) was a breakthrough in the treatment of these cancers. However, 15–20% of tumors harbor primary resistance to this therapy, and moreover, patients develop acquired resistance to treatment. Understanding the molecular phenomena behind resistance to BRAFi/MEKis is indispensable in order to develop novel targeted therapies. Most often, resistance develops due to either the reactivation of the MAPK/ERK pathway or the activation of alternative kinase signaling pathways including phosphatase and tensin homolog (PTEN), neurofibromin 1 (NF-1) or RAS signaling. The hyperactivation of tyrosine kinase receptors, such as the receptor of the platelet-derived growth factor β (PDFRβ), insulin-like growth factor 1 receptor (IGF-1R) and the receptor for hepatocyte growth factor (HGF), lead to the induction of the AKT/3-phosphoinositol kinase (PI3K) pathway. Another pathway resulting in BRAFi/MEKi resistance is the hyperactivation of epidermal growth factor receptor (EGFR) signaling or the deregulation of microphthalmia-associated transcription factor (MITF).

show abstract

Epidermal growth factor receptor (EGFR) expression in cutaneous melanoma: A possible role as prognostic marker

Cited by 4 publications

References 0 publications

Theranostic Activity of Ceria-Based Nanoparticles toward Parental and Metastatic Melanoma: 2D vs 3D Models

Theranostic Activity of Ceria-Based Nanoparticles toward Parental and Metastatic Melanoma: 2D vs 3D Models

The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer

Targeted Therapy in Melanoma and Mechanisms of Resistance

Contact Info

Product

Resources

About